influenza
virus
iav
still
pose
substanti
burden
human
health
worldwid
econom
season
influenza
virus
respons
death
annual
immunocompromis
individu
particularli
high
risk
sever
cours
infect
appear
transmiss
pandem
iav
strain
caus
devast
outbreak
past
addit
threaten
global
health
urg
discoveri
new
antivir
cellular
factor
involv
viral
replic
propos
attract
target
antivir
among
kinas
particularli
promis
kinas
inhibitor
compris
drugdiscoveri
program
pharmaceut
iav
har
cellular
endocyt
machineri
enter
cell
traffic
cytoplasm
reach
replic
site
nucleu
coordin
earli
activ
signal
pathway
shown
import
viral
identif
key
kinas
involv
process
could
contribut
develop
new
antivir
bind
iav
particl
interact
viral
hemagglutinin
ha
expos
sialyl
protein
epitheli
propos
induc
format
lipid
raftbas
signal
platform
receptor
tyrosin
kinas
rtk
epiderm
growth
factor
receptor
egfr
cmet
cluster
activ
rtk
lead
intern
endocyt
vesicl
viral
particl
could
downstream
initi
rtksignal
earli
activ
kinas
shown
promot
iav
togeth
extracellular
signalregul
kinas
enhanc
activ
vacuolartyp
hatpas
vatpas
essenti
endosom
acidif
lead
viral
focal
adhes
kinas
fak
propos
establish
link
activ
cytoskeleton
reorgan
requir
viral
endosom
activ
protein
kinas
c
pkc
shown
play
role
iav
traffick
late
recent
signal
also
implic
clathrindepend
clathrinindepend
iav
entri
mechan
via
intric
associ
regulatori
howev
systemat
unbias
analysi
main
signal
rout
initi
iav
bind
key
mediat
requir
subsequ
infect
still
lack
conduct
silacbas
quantit
phosphoproteom
analysi
human
lung
epitheli
cell
within
minut
postinfect
quantifi
phosphoryl
statu
around
differ
phosphoryl
site
protein
identifi
infectioninduc
chang
phosphoryl
pattern
basi
virusinduc
phosphosignatur
abl
identifi
kinas
g
proteincoupl
receptor
kinas
activ
iav
entri
respons
observ
signal
landscap
inhibit
kinas
activ
sever
decreas
iav
uncoat
inhibit
viral
replic
primari
human
airway
epitheli
cultur
well
anim
model
iav
pathogenesi
result
therefor
establish
promis
drug
target
next
gener
antivir
influenza
viru
order
identifi
cellular
kinas
requir
iav
entri
cell
conduct
quantit
phosphoproteom
screen
human
lung
epitheli
cell
hypothes
viru
bind
host
cell
would
alreadi
induc
signal
cascad
enabl
follow
step
replic
cycl
tyrosin
phosphoryl
epiderm
growth
factor
receptor
egfr
shown
induc
ha
bind
host
monitor
egfr
phosphoryl
upon
infect
cell
iav
strain
moi
pfucel
observ
strong
activ
egfr
min
post
infect
pi
therefor
select
time
point
analysi
supplementari
figur
accur
quantif
phosphoryl
dynam
perform
five
biolog
replic
cell
subject
tripl
isotop
label
amino
acid
cell
cultur
silac
peptid
phosphoryl
serin
threonin
residu
enrich
identifi
quantifi
liquid
chromatographi
coupl
tandem
mass
spectrometri
lcmsm
fig
use
iav
grown
embryon
chicken
egg
analysi
avoid
contribut
cytokin
interferon
act
mostli
speciesspecif
manner
addit
also
perform
proteom
analysi
chicken
protein
present
viru
stock
allanto
fluid
mockinfect
egg
use
mock
condit
supplementari
data
detect
chicken
protein
least
abund
compar
mock
allow
us
attribut
differ
phosphoryl
viru
infect
abl
detect
differ
phosphosit
per
experiment
condit
around
phosphopeptid
belong
protein
supplementari
figur
raw
data
supplementari
data
expect
vast
major
detect
phosphosit
phosphoserin
threonin
modif
phosphotyrosin
total
phosphosit
detect
one
biolog
replic
good
correl
supplementari
figur
quantit
analysi
perform
use
reveal
chang
phosphoryl
import
subset
phosphopeptid
within
minut
viru
addit
absolut
peptid
abund
quantifi
total
extract
digest
remain
mostli
unalt
use
cutoff
valu
chang
fc
compar
mock
infect
sampl
phosphosit
found
differenti
phosphoryl
min
postinocul
fig
dephosphoryl
show
increas
phosphoryl
min
addit
viru
chang
phosphoryl
pronounc
site
differenti
phosphoryl
fig
dephosphoryl
show
increas
phosphoryl
data
reveal
differ
cellular
signal
pathway
activ
within
minut
iav
infect
possibl
induc
viru
bind
cell
surfac
determin
cellular
function
regul
phosphoryl
earli
iav
infect
analyz
cellular
pathway
protein
contain
iavrespons
phosphosit
assign
distribut
annot
kegg
kyoto
encyclopaedia
gene
genom
among
differenti
phosphoryl
protein
either
min
postinfect
compar
background
total
popul
identifi
phosphoryl
protein
fig
supplementari
tabl
protein
describ
function
mapk
signal
adj
p
valu
hypergeometr
test
endocytosi
adj
p
valu
hypergeometr
test
regul
actin
cytoskeleton
adj
p
valu
hypergeometr
test
overrepres
among
protein
phosphoryl
respons
infect
cellular
function
known
requir
iav
entri
result
valid
experiment
furthermor
protein
relat
focal
adhes
tight
junction
adj
p
valu
hypergeometr
test
thu
far
describ
involv
earli
stage
iav
infect
found
significantli
enrich
among
integrin
actinbind
protein
parvin
parva
filamin
flnb
protein
relat
actinmembran
attach
pxn
vapa
differ
cytoskeleton
compon
previous
associ
viral
entri
phosphoryl
within
minut
infect
also
gener
network
analyz
differenti
phosphoryl
protein
interconnect
within
differ
pathway
identifi
clear
crosstalk
fig
main
goal
reveal
novel
drug
target
iav
next
focus
kinas
activ
respons
infect
aim
develop
bioinformat
pipelin
identifi
cellular
kinas
could
respons
phosphoryl
iavrespons
phosphosit
data
set
approach
centr
kinas
predict
obtain
groupbas
predict
system
gp
includ
redefin
high
stringenc
cutoff
see
method
supplementari
figur
gp
rank
likelihood
particular
kinas
kinas
famili
phosphoryl
given
residu
consid
amino
acid
surround
phosphoryl
site
put
kinas
hyperphosphoryl
site
min
postinfect
identifi
distribut
top
predict
iavrespons
kinas
compar
background
kinas
predict
total
popul
identifi
phosphopeptid
fig
put
substrat
mitogenactiv
protein
kinas
map
kinaseinteract
serinethreonineprotein
kinas
p
valu
fisher
exact
test
p
valu
fisher
exact
test
top
hit
among
hyperphosphoryl
peptid
min
iav
bind
predict
substrat
cyclindepend
kinas
pololik
kinas
p
valu
fisher
exact
test
significantli
phosphoryl
min
addit
viru
interestingli
g
proteincoupl
receptor
kinas
activ
kinas
rhoassoci
coiledcoil
contain
protein
kinas
p
valu
fisher
exact
test
like
kinas
p
valu
fisher
exact
test
predict
activ
timepoint
analyz
kinas
like
mapk
mnk
mapkerk
signal
alreadi
implic
viral
entri
thu
valid
analysi
howev
also
reveal
cdk
novel
kinas
activ
earli
step
iav
replic
next
amino
acid
adjac
hyperphosphoryl
posit
min
postinfect
analyz
identifi
conserv
sequenc
could
link
recognit
motif
predict
kinas
identifi
four
sequenc
enrich
among
iavrespons
phosphopeptid
fig
prolin
p
posit
particularli
overrepres
among
put
target
cdk
mapk
agreement
result
motif
part
optim
recognit
sequenc
propos
cdk
erk
mapk
whose
activ
shown
requir
iav
arginin
r
posit
also
enrich
among
iavrespons
phosphopeptid
especi
among
put
target
particular
featur
part
optim
recognit
sequenc
predict
pkc
pka
kinas
link
iav
entri
final
glutam
acid
e
posit
serin
posit
likewis
associ
iavrespons
phosphosit
among
put
target
analysi
next
evalu
whether
viral
replic
could
reduc
target
silicoidentifi
iavrespons
kinas
small
molecular
weight
compound
inhibitor
fig
test
effect
specif
methyl
vinyl
inhibitor
replic
luciferaseencod
report
iav
togeth
kinas
predict
activ
iav
timepoint
analyz
fig
inhibitor
commerci
avail
exclud
analysi
also
includ
cdk
inhibitor
cdk
key
cellular
kinas
link
earli
step
iav
infect
given
mapk
pathway
broadli
implic
viral
among
top
hit
pathway
enrich
analysi
fig
specif
erk
inhibitor
ulixertinib
also
includ
posit
control
cytotox
differ
compound
cell
determin
supplementari
figur
concentr
without
deleteri
effect
use
experi
expect
erk
inhibitor
effici
block
viru
replic
dosedepend
manner
fig
inhibit
partial
reduc
viral
replic
consist
previou
report
role
iav
could
observ
signific
effect
upon
target
experiment
system
cdk
inhibitor
effici
block
viral
replic
confirm
predict
kinas
activ
profil
fig
case
inhibit
viral
replic
clearli
observ
h
postinfect
hpi
suggest
predict
phosphoproteom
data
cdk
requir
earli
step
viral
replic
cycl
order
explor
possibl
target
inhibit
iav
first
assess
impact
deplet
viral
growth
cell
transfect
four
differ
small
interf
rna
sirna
target
scrambl
sirna
siscr
control
sirna
target
vatpas
requir
endosom
acidif
viral
entri
first
silenc
effici
supplementari
figur
impact
cell
viabil
supplementari
figur
differ
sirna
analyz
four
sirna
reduc
express
compar
level
minor
effect
cell
viabil
h
postsirna
transfect
cell
infect
iav
low
multipl
infect
moi
pfucel
supernat
harvest
h
h
later
fig
sirna
reduc
viral
titer
support
role
host
factor
requir
iav
infect
next
perform
similar
experi
sirnatr
cell
use
human
iav
strain
fig
highli
pathogen
avian
strain
fig
deplet
also
inhibit
replic
virus
final
discard
celllinespecif
requir
also
transfect
sirna
target
describ
control
human
lung
fibroblast
subsequ
infect
supplementari
figur
e
although
viru
abl
replic
effici
cell
deplet
significantli
impair
viral
replic
cell
line
one
top
hit
predict
respons
observ
iavinduc
phosphoryl
signatur
hypothes
activ
iav
previou
report
show
differenti
phosphoryl
regul
thu
specul
phosphoryl
statu
would
chang
respons
iav
infect
howev
detect
phosphopeptid
deriv
proteom
analysi
possibl
suggest
activ
tyrosin
phosphoryl
order
assess
phosphoryl
statu
respons
iav
employ
phosphat
affin
polyacrylamid
gel
method
make
use
compound
bind
phosphat
group
therebi
specif
slow
migrat
phosphoryl
protein
gel
electrophoresi
enabl
visual
differenti
phosphoryl
form
given
protein
egf
report
induc
tyrosin
phosphoryl
valid
method
transfect
cell
construct
encod
egfr
treat
cell
epiderm
growth
factor
egf
min
perform
phosphat
affin
polyacrylamid
gel
control
treat
lysat
lambda
protein
phosphatas
lpp
cell
stimul
egf
observ
stronger
signal
phosphoryl
version
present
sampl
treat
lpp
fig
importantli
also
observ
appear
phosphoryl
form
upon
iav
infect
fig
confirm
hypothesi
phosphoryl
within
minut
infect
activ
kinas
often
lead
transloc
also
analyz
local
respons
iav
infect
use
egf
treatment
posit
control
shown
transloc
egfrposit
cluster
plasma
membran
upon
egfr
interestingli
found
iav
infect
also
induc
transloc
plasma
membran
cluster
coloc
egfr
fig
supplementari
figur
transloc
also
observ
use
purifi
stock
iav
supplementari
figur
allow
us
attribut
activ
viral
particl
rule
contribut
allanto
fluid
compon
note
iavinduc
transloc
depend
egfr
could
observ
cell
lack
egfr
express
fig
thu
conclud
iav
infect
induc
phosphoryl
transloc
egfrposit
membran
cluster
result
thu
far
hypothes
kinas
activ
requir
earli
step
viral
replic
cycl
verifi
perform
time
addit
experi
inhibitor
ad
cell
differ
time
postinfect
fig
addit
compound
togeth
viru
inoculum
effici
reduc
replic
renilla
luciferaseencod
report
iav
ad
inhibitor
hpi
reduc
viral
replic
less
effici
addit
inhibitor
later
time
point
affect
progress
infect
furthermor
addit
compound
viru
bind
first
h
infect
follow
wash
step
replac
inhibitorfre
medium
suffici
block
replic
report
viru
fig
verifi
observ
perform
similar
experi
use
iav
strain
supernat
inhibitortr
infect
cell
collect
hpi
viru
titer
determin
plaqu
assay
fig
addit
inhibitor
first
h
infect
suffici
reduc
viral
product
confirm
requir
activ
earli
step
viral
cycl
next
evalu
amount
viral
nucleoprotein
np
within
cell
nucleu
hpi
direct
measur
earli
infect
progress
cell
pretreat
h
subsequ
infect
high
multipl
infect
moi
pfucel
h
presenc
inhibitor
analyz
confoc
microscopi
fig
controltr
cell
np
clearli
detect
nucleu
consequ
ongo
viral
replic
howev
use
posit
control
effici
block
nuclear
np
accumul
similar
result
obtain
cell
transfect
sirna
target
supplementari
figur
translat
block
similar
experiment
setup
addit
cycloheximid
order
detect
incom
viral
ribonucleoprotein
vrnp
nuclear
accumul
np
sever
impair
presenc
fig
suggest
activ
kinas
requir
nuclear
import
parent
vrnp
test
whether
requir
viru
intern
endosom
traffick
cell
pretreat
h
equival
amount
solvent
dimethyl
sulfoxid
dmso
prior
infect
min
moi
pfucel
quantifi
amount
virion
earli
endosom
perform
confoc
immunofluoresc
analysi
np
earli
endosom
antigen
measur
percentag
coloc
use
imari
signific
differ
coloc
intern
virion
observ
cell
treat
inhibitor
supplementari
figur
suggest
requir
bind
intern
earli
endosom
traffick
next
character
whether
function
necessari
effici
viral
fusion
gener
iav
viruslik
particl
vlp
contain
ha
na
strain
harbor
betalactamas
report
protein
fuse
influenza
matrix
upon
fusion
viral
endosom
membran
gain
access
cytoplasm
cleav
fluorogen
substrat
shift
shorter
fluoresc
emiss
wavelength
detect
flow
cytometri
although
impair
effici
block
nuclear
accumul
np
mdck
cell
hpi
nontox
concentr
grki
supplementari
figur
differ
viral
fusion
detect
presenc
inhibitor
supplementari
figur
next
evalu
whether
requir
uncoat
process
protein
core
dissoci
vrnp
allow
releas
cytosol
infect
cell
cell
infect
moi
pfucel
h
presenc
inhibitor
equival
amount
solvent
dmso
determin
effici
uncoat
process
perform
confoc
immunofluoresc
analysi
antibodi
target
epitop
sole
access
quantifi
intens
stain
use
imagej
dmsotreat
cell
consequ
uncoat
virion
epitop
recogn
antibodi
expos
green
stain
observ
across
cytoplasm
howev
upon
treatment
inhibit
intens
stain
significantli
reduc
confin
discret
structur
cytoplasm
fig
altogeth
result
map
requir
viral
uncoat
process
given
role
viral
np
protein
uncoat
also
analyz
phosphoryl
statu
protein
absenc
presenc
inhibitor
observ
phosphoryl
np
found
phosphoryl
supplementari
figur
line
publish
result
phosphoryl
statu
viru
howev
differ
observ
inhibitortr
untreat
sampl
supplementari
figur
suggest
exert
provir
function
via
cellular
rather
viral
target
next
test
antivir
activ
paroxetin
select
serotonin
reuptak
inhibitor
ssri
recent
shown
also
inhibit
activ
vitro
cell
cultur
fig
paroxetin
effici
block
iav
replic
dosedepend
manner
slightli
effici
inhibitor
use
previou
experi
control
ssri
fluoxetin
inhibit
iav
infect
supplementari
figur
suggest
paroxetin
inhibit
iav
via
inhibit
rather
function
ssri
wide
use
model
iav
infect
repres
complex
human
airway
epithelia
therefor
evalu
antivir
activ
inhibitor
primari
human
bronchial
epitheli
cell
differenti
pseudostratifi
human
airway
epitheli
hae
cultur
airliquidinterfac
ali
fulli
differenti
hae
cultur
differ
donor
pretreat
inhibitor
h
subsequ
infect
human
iav
strain
h
presenc
inhibitor
fig
compound
block
nuclear
accumul
np
effici
viru
strain
paroxetin
potent
infect
hae
cultur
differ
strain
iav
collect
supernat
hpi
quantifi
viru
product
plaqu
assay
fig
paroxetin
reduc
viru
titer
strain
test
confirm
block
activ
could
use
limit
iav
infect
human
lung
epithelia
final
test
whether
chemic
inhibit
could
reduc
viral
replic
sever
infect
mice
data
avail
stabil
bioavail
grki
vivo
select
paroxetin
use
mice
week
old
j
mice
inject
intraperiton
ip
mgkg
paroxetin
equival
amount
solvent
h
post
treatment
mice
challeng
pfu
mouseadapt
inocul
phosphatebuff
salin
pb
via
intranas
rout
paroxetin
solvent
treatment
repeat
day
infect
day
post
infect
pi
one
group
mice
weight
loss
surviv
monitor
signific
chang
observ
paroxetinetr
group
solvent
control
group
supplementari
figur
c
second
group
mice
viru
titer
pi
determin
snout
lung
homogen
track
progress
infect
upper
urt
lower
respiratori
tract
lrt
fig
h
signific
differ
observ
viru
titer
pi
howev
paroxetin
treatment
decreas
viru
titer
significantli
organ
pi
summari
result
show
inhibit
led
strongli
reduc
viral
titer
primari
human
airway
cultur
also
limit
viral
replic
mous
model
howev
inhibit
could
protect
mice
weight
loss
death
lethal
challeng
model
vivo
studi
use
potent
inhibitor
need
fulli
assess
potenti
inhibit
therapeut
option
result
establish
novel
drug
target
candid
influenza
bind
iav
host
cell
trigger
complex
signal
cascad
regul
intern
viru
also
impact
later
event
infect
cycl
order
obtain
global
pictur
virusinduc
signal
event
unbias
manner
appli
quantit
phosphoproteom
cell
infect
influenza
virus
min
reveal
uniqu
iavinduc
phosphoryl
signatur
even
though
approach
limit
identif
phosphoserin
threonin
contain
peptid
includ
phosphotyrosin
uncov
infectioninduc
chang
phosphoryl
statu
cellular
protein
within
minut
viru
addit
found
mapk
pathway
promin
signal
cascad
induc
known
pathway
becom
activ
respons
studi
reveal
central
role
earli
stage
influenza
viru
infect
main
goal
uncov
novel
drug
target
influenza
focus
identif
kinas
could
respons
observ
chang
phosphoryl
similar
analysi
phosphatas
would
equal
interest
thu
far
bioinformat
tool
phosphatas
predict
less
well
develop
found
predict
involv
phosphoryl
event
identifi
time
point
analyz
role
iav
entri
propos
implic
influenza
viru
infect
yet
interact
escrtiii
complex
function
cytokinet
absciss
specif
requir
delay
cell
divis
chromosom
segreg
regard
virus
found
upregul
cytomegaloviru
infect
function
relev
observ
knowledg
specif
inhibitor
develop
yet
thu
suitabl
potenti
drug
target
influenza
current
limit
contrast
target
intens
research
effort
kinas
best
known
role
gproteincoupl
receptor
gpcr
signal
recruit
receptor
upon
activ
phosphoryl
gpcr
turn
lead
bind
betaarrestin
receptor
impair
downstream
signal
therebi
lead
rapid
desensit
furthermor
betaarrestin
bind
also
trigger
receptor
intern
subsequ
lysosom
increas
level
therefor
associ
reduct
gpcr
signal
particularli
well
document
betaadrenerg
receptor
signal
heart
tissu
increas
level
link
impair
cardiac
henc
emerg
promis
drug
target
heart
diseas
inhibitor
develop
could
eventu
enabl
drug
repurpos
treatment
influenza
viru
infect
point
target
kinas
exert
provir
function
iav
known
describ
betaarrestin
beststudi
substrat
detect
phosphopeptid
deriv
betaarrestin
proteom
analysi
furthermor
data
metaanalysi
sever
genomewid
rnai
screen
requir
host
factor
suggest
betaarrestin
requir
host
factor
iav
therefor
like
mediat
provir
function
note
recent
describ
key
stimul
histon
deacetylas
turn
propos
recruit
viral
fusion
site
enabl
effici
uncoat
complex
mechan
involv
aggresom
process
howev
phosphoryl
shown
stimul
deacetylas
activ
requir
viral
uncoat
addit
phosphopeptid
detect
analysi
suggest
exert
provir
role
also
observ
chang
phosphoryl
statu
viral
protein
np
presenc
inhibitor
specul
support
viral
uncoat
process
phosphoryl
noncanon
cellular
target
character
interplay
compon
aggresom
system
cellular
cytoskeleton
help
reveal
molecular
mechan
iav
uncoat
interestingli
recent
shown
promot
entri
rna
synthesi
yellow
fever
viru
yfv
dengu
viru
denv
hepat
c
viru
hcv
flavivirus
caus
sever
diseas
human
togeth
find
key
kinas
involv
initi
step
iav
infect
suggest
inhibit
function
may
repres
promis
opportun
develop
broad
spectrum
antivir
summari
work
reveal
uniqu
phosphoryl
signatur
induc
iav
within
minut
infect
identifi
lead
target
host
celldirect
antivir
follow
compound
use
dimethyl
sulfoxid
dmso
sigmaaldrich
bafilomycin
sigmaaldrich
cdk
inhibitor
selleckchem
ulixertinib
mapk
inhibitor
selleckchem
inhibitor
selleckchem
inhibitor
selleckchem
methyl
vinyl
inhibitor
santa
cruz
biotechnolog
cycloheximid
sigmaaldrich
paroxetin
inhibitor
sigmaaldrich
western
blot
immunofluoresc
follow
primari
antibodi
use
rabbit
polyclon
antibodi
santa
cruz
biotechnolog
western
blot
dilut
mous
monoclon
antibodi
santa
cruz
biotechnolog
western
blot
dilut
rabbit
polyclon
antihegfr
santa
cruz
biotechnolog
immunofluoresc
dilut
western
blot
dilut
mous
monoclon
anti
hatag
cell
signal
immunofluoresc
dilut
rabbit
polyclon
antinp
antibodi
western
blot
kind
gift
nieto
centro
nacion
de
madrid
spain
western
blot
dilut
rabbit
polyclon
antinp
antibodi
immunofluoresc
kind
gift
p
pales
mount
sinai
hospit
ny
usa
immunofluoresc
dilut
mous
monoclon
antinp
atcc
immunofluoresc
dilut
mous
monoclon
antibodi
atcc
immunofluoresc
western
blot
dilut
rabbit
polyclon
antiiav
thermofish
western
blot
dilut
mous
monoclon
antibodi
bd
bioscienc
immunofluoresc
obtain
atcc
kind
gift
j
pavlov
institut
medic
virolog
zurich
switzerland
mdck
kindli
provid
ben
hale
institut
medic
virolog
zurich
switzerland
mdck
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
vv
fetal
bovin
serum
fb
vv
penicillin
streptomycin
life
technolog
maintain
minim
essenti
eagl
medium
mem
sigmaaldrich
supplement
vv
fetal
bovin
serum
fb
vv
penicillin
streptomycin
life
technolog
isol
cultiv
primari
human
bronchial
epitheli
cell
form
pseudostratifieddifferenti
human
airway
epitheli
hae
cultur
perform
describ
influenza
viru
strain
kindli
provid
p
pales
mount
sinai
hospit
ny
usa
strain
kind
gift
j
pavlov
institut
medic
virolog
zurich
switzerland
viru
stock
grown
old
embryon
chicken
egg
titer
plaqu
assay
mdck
cell
viru
infect
cell
wash
pb
supplement
wv
bovin
serum
albumin
bsa
vv
penicillinstreptomycin
infect
pb
case
hae
cultur
three
wash
infect
pb
perform
moiadjust
inoculum
subsequ
ad
cell
incub
h
room
temperatur
rt
h
ice
case
infect
synchron
need
adsorpt
time
inoculum
remov
replac
appropri
amount
postinfect
medium
dmem
supplement
bsa
mm
hepe
penicillinstreptomycin
cell
incub
indic
time
infecti
particl
supernat
cell
quantifi
plaqu
assay
mdck
cell
initi
analysi
includ
supplementari
figur
proteom
profil
human
phosphortk
array
kit
r
system
use
briefli
cell
seed
plate
serumstarv
overnight
follow
day
cell
infect
moi
pfucel
min
lyse
lysat
use
accord
manufactur
protocol
membran
read
use
luminesc
imag
analyz
system
fujifilm
signal
intens
quantifi
imagej
five
biolog
replic
phosphoproteom
experi
perform
use
silaclabel
cell
replic
two
flask
cell
label
follow
condit
use
l
light
cell
grown
normal
dmem
medium
cell
grown
dmem
contain
lysin
arginin
h
heavi
cell
grown
dmem
contain
lysin
arginin
incorpor
differ
isotop
confirm
lcmsm
medium
heavi
label
cell
infect
iav
moi
pfucel
min
respect
viru
inoculum
prepar
infect
pb
mockinfect
control
equival
amount
allanto
fluid
noninfect
old
embryon
chicken
egg
dilut
infect
pb
ad
unlabel
cell
l
correspond
incub
time
cell
directli
lyse
sdslysi
buffer
wv
sd
mm
trishcl
ph
dtt
complet
roch
phosstop
roch
differ
cell
extract
pool
sonic
briefli
reduc
viscos
order
concentr
sampl
protein
precipit
use
four
volum
aceton
incub
overnight
follow
centrifug
g
h
precipit
protein
pellet
wash
three
time
aceton
dri
min
protein
pellet
solubil
smaller
volum
sdslysi
buffer
protein
concentr
differ
replic
determin
use
qubit
fluoromet
invitrogen
protein
extract
process
use
filteraid
sampl
prepar
fasp
briefli
protein
dilut
urea
buffer
urea
mm
trishcl
ph
load
centrifug
filter
unit
membran
millipor
protein
bound
membran
centrifug
alkyl
use
mm
iodoacetamid
iaa
solut
urea
buffer
wash
three
time
urea
buffer
protein
wash
twice
mm
nacl
three
time
use
mm
triethylammonium
bicarbon
teab
buffer
ph
overnight
onfilt
digest
perform
trypsin
promega
ratio
ww
trypsin
protein
wet
chamber
tryptic
peptid
elut
filter
centrifug
second
elut
use
mm
teab
buffer
perform
increas
yield
fraction
peptid
collect
total
proteom
analysi
phosphopeptid
enrich
metal
affin
chromatographi
tiimac
affin
chromatographi
use
magnet
microspher
resyn
bioscienc
magnet
separ
thermo
fisher
scientif
mg
tiimac
magnet
microspher
wash
twice
vv
ethanol
equilibr
three
time
phosphopeptid
load
buffer
glycol
acid
vv
acetonitril
acn
vv
trifluoroacet
acid
tfa
tryptic
peptid
dilut
load
buffer
ad
mg
equilibr
magnet
microspher
incub
min
rt
continu
rotat
bind
phosphopeptid
microspher
wash
load
buffer
unbound
peptid
remov
three
wash
wash
buffer
vv
acn
vv
tfa
phosphopeptid
elut
incub
microspher
min
elut
buffer
vv
acidifi
addit
vv
formic
acid
fa
dri
speedvac
concentr
thermo
fisher
scientif
peptid
resuspend
vv
acn
vv
tfa
desalt
use
ziptip
millipor
filter
equilibr
vv
acn
vv
tfa
subsequ
twice
vv
tfa
solut
peptid
bound
filter
wash
three
time
vv
tfa
elut
vv
acn
vv
tfa
dri
speedvac
concentr
peptid
dissolv
lcmsm
solvent
vv
acn
vv
fa
prior
lcmsm
analysi
data
acquir
orbitrap
fusion
tribrid
mass
spectromet
thermo
scientif
san
jose
ca
connect
easynlc
hplc
system
thermo
scientif
peptid
sampl
formic
acid
load
onto
frit
column
inner
diamet
length
cm
pack
revers
phase
materi
particl
size
pore
size
dr
maisch
gmbh
germani
separ
flow
rate
nlper
min
solvent
composit
buffer
formic
acid
water
buffer
b
contain
formic
acid
acetonitril
phosphoenrich
sampl
follow
lc
gradient
appli
min
buffer
b
min
b
min
b
min
b
survey
scan
record
orbitrap
mass
analyz
rang
mz
resolut
maximum
inject
time
ms
higher
energi
collision
dissoci
hcd
spectra
acquir
ion
trap
mass
analyz
use
normal
collis
energi
precursor
ion
isol
width
set
mz
maximum
inject
time
ms
agc
target
valu
appli
charg
state
screen
enabl
charg
state
includ
threshold
signal
intens
precursor
mass
alreadi
select
msm
acquisit
exclud
select
total
protein
sampl
follow
lc
gradient
appli
min
buffer
b
min
b
min
b
min
b
survey
scan
record
rang
mz
resolut
maximum
inject
time
ms
hcd
spectra
acquir
ion
trap
use
normal
collis
energi
isol
window
mz
maximum
inject
time
ms
agc
target
valu
intens
threshold
dynam
exclus
durat
first
round
peptid
identif
conduct
mascot
wwwmatrixsciencecom
phosphoenrich
effici
number
identif
differ
sampl
evalu
use
scaffold
ptm
mass
spectrometri
proteom
data
deposit
proteomexchang
consortium
via
partner
repositori
data
set
identifi
data
acquir
orbitrap
fusion
analyz
maxquant
search
targetdecoy
databas
consist
human
forward
uniprot
entri
influenza
viru
forward
uniprot
entri
sequenc
addit
control
databas
contain
chicken
sequenc
forward
uniprot
entri
use
identif
iavinduc
chicken
protein
egggrown
stock
identifi
contamin
protein
intern
contamin
databas
maxquant
use
search
paramet
cystein
carbamidomethyl
fix
modif
protein
ntermin
acetyl
methionin
oxid
phosphoryl
serin
threonin
tyrosin
variabl
modif
silac
label
heavi
label
enzym
trypsinp
two
miss
cleavag
allow
minimum
seven
amino
acid
per
identifi
peptid
requir
precursor
ion
mass
toler
set
ppm
fragment
mass
toler
set
ppm
peptid
identif
accept
less
revers
hit
retain
list
protein
fals
discoveri
rate
fdr
set
phosphopeptid
data
set
median
maxquant
ratio
differ
replic
calcul
data
tiimac
base
approach
combin
analysi
identifi
top
enrich
pathway
distribut
annot
kegg
among
differenti
phosphoryl
peptid
min
post
infect
compar
background
detect
protein
ms
analysi
plu
one
previous
identifi
phosphoproteom
character
hiv
supplementari
figur
kegg
pathway
whole
popul
retriev
r
packag
orghsegdb
v
keggdb
v
standard
hypergeometr
test
perform
follow
bonferroni
correct
enrich
result
present
context
kegg
pathway
topolog
use
igraph
kinas
predict
deriv
high
stringenc
score
calcul
use
groupbas
predict
system
gp
http
gpsbiocuckooorgonlinephp
rank
likelihood
particular
kinas
kinas
famili
phosphoryl
given
residu
consid
amino
acid
surround
phosphoryl
site
predict
experiment
detect
phosphoryl
site
rank
base
differ
site
threshold
site
predict
score
supplementari
figur
order
determin
select
paramet
would
use
given
one
kinas
may
respons
phosphoryl
given
protein
given
posit
first
work
subset
entri
phosphoelm
april
http
phosphoelmeuorgdatasethtml
briefli
download
abstract
n
associ
kinasephosphosit
pair
rentrez
select
report
context
viral
infect
n
uniqu
site
uniqu
protein
repres
substrat
major
kinas
group
supplementari
figur
subsequ
ran
gp
full
sequenc
protein
check
condit
allow
us
retriev
mani
true
posit
per
phosphosit
pi
predict
pi
supplementari
figur
c
use
stringent
fals
posit
rate
serinethreonin
kinas
tyrosin
kinas
predict
threshold
top
five
predict
term
gpscalcul
score
indic
similar
detect
phosphosit
phosphosit
gold
standard
phosphoelm
deriv
paramet
delta
defin
differ
gpscalcul
score
gpsprovid
cutoff
per
posit
found
includ
true
posit
scenario
chosen
cutoff
kinasephosphosit
pair
report
top
predict
kinas
differenti
phosphoryl
site
min
post
infect
consid
iavrespons
kinas
distribut
top
predict
kinas
compar
background
total
detect
peptid
popul
enrich
hit
identifi
determin
enrich
particular
kinas
signific
perform
random
select
peptid
peptid
detect
assay
number
peptid
sampl
per
random
equal
size
hyperphosphoryl
peptid
min
post
infect
wrt
mock
subsequ
compar
frequenc
top
kinas
predict
detect
versu
random
condit
use
fisher
exact
test
subset
top
predict
kinas
signific
enrich
establish
given
higher
variabl
score
ensur
inclus
top
call
phosphosit
kinas
predict
supplementari
figur
other
includ
tend
toward
enrich
p
valu
fisher
exact
test
consequ
exclud
potenti
contribut
viral
replic
includ
analysi
comput
code
avail
upon
request
find
motif
potenti
link
phosphoryl
site
associ
kinas
predict
first
group
sequenc
within
amino
acid
detect
phosphoryl
site
ie
phosphoryl
site
posit
sequenc
includ
one
group
base
assumpt
differ
kinas
may
respons
phosphoryl
given
protein
given
posit
sequenc
link
predict
kinas
group
submit
weblogo
http
weblogoberkeleyedulogocgi
motif
detect
supplementari
figur
order
quantit
measur
effect
differ
chemic
viral
replic
use
report
iav
deriv
code
sequenc
hemagglutinin
protein
replac
renilla
luciferas
allow
realtim
determin
viral
differ
kinas
inhibitor
ad
cell
togeth
report
viru
moi
pfucel
synchron
infect
allow
viru
bind
target
cell
h
inoculum
remov
fresh
cultur
medium
contain
renilla
luciferas
substrat
enduren
live
cell
substrat
promega
indic
concentr
differ
inhibitor
ad
cell
plate
transfer
realtim
luminesc
measur
perform
differ
timepoint
indic
use
envis
multilabel
reader
perkin
elmer
cell
revers
transfect
nm
sirna
qiagen
dilut
optimem
life
technolog
use
rnaimax
reagent
accord
manufactur
protocol
invitrogen
h
posttransfect
cell
either
infect
cell
viabil
determin
use
celltiterglo
assay
promega
addit
celltiterglo
kit
use
assess
effect
differ
inhibitor
cell
absenc
infect
cell
extract
prepar
use
laemmli
buffer
mm
trishcl
ph
glycerol
sd
mm
dtt
bromophenol
blue
sampl
subject
standard
sdspage
protein
transfer
nitrocellulos
membran
hybond
ecl
ge
healthcar
indic
primari
antibodi
use
fluoresc
secondari
antibodi
licor
imag
acquir
odissey
fc
imag
system
sampl
prepar
cell
lyse
use
ph
neutral
buffer
mm
trishcl
ph
vv
mm
nacl
complet
edtafre
proteas
inhibitor
cocktail
roch
phosstop
roch
laemmli
buffer
ad
gel
cast
accord
manufactur
protocol
wakochem
use
mw
wako
cat
sampl
run
sd
page
gel
h
v
blot
night
onto
nitrocellulos
membran
hybond
ecl
ge
healthcar
stain
analysi
done
describ
standard
sdspage
blot
shown
fig
e
uncrop
version
blot
provid
supplementari
figur
cell
grown
glass
coverslip
plate
transfect
kind
gift
dr
u
quitter
eth
zurich
switzerland
kind
gift
mienchi
hung
addgen
plasmid
use
viafect
promega
transfect
reagent
infect
moi
pfucel
stimul
hregf
ngml
cell
process
immunofluoresc
describ
immunofluoresc
stain
mdck
cell
grown
glass
coverslip
plate
case
hae
cultur
cell
fix
stain
directli
membran
infect
cell
fix
paraformaldehyd
pfa
permeabil
use
immunofluoresc
buffer
pb
supplement
mm
saponin
bsa
min
buffer
cell
incub
overnight
correspond
primari
antibodi
dilut
buffer
cell
wash
three
time
buffer
incub
secondari
antibodi
dilut
dapicontain
buffer
h
rt
alexa
fluorconjug
donkey
antimouserabbit
antibodi
catalog
life
technolog
use
secondari
antibodi
cell
wash
three
time
buffer
coverslip
membran
dip
deioniz
water
invers
mount
onto
glass
microscop
slide
use
prolong
gold
antifad
mountant
thermo
fisher
scientif
microscopi
imag
acquir
confoc
laser
scan
microscop
leica
quantif
nuclear
np
signal
perform
use
autom
macro
imagej
statist
analysi
differ
imag
done
use
prism
softwar
endosom
coloc
analysi
imari
softwar
use
standard
coloc
set
mask
vlp
harbor
fusion
protein
produc
essenti
describ
tschern
briefli
hek
cell
seed
onto
polyllysineco
sigmaaldrich
plate
transfect
optimem
life
technolog
ng
pcaggswsnha
ng
pcaggswsnna
per
well
use
viafect
promega
transfect
reagent
dna
medium
exchang
h
posttransfect
optimem
life
technolog
contain
penicillinstreptomycin
vlp
collect
h
transfect
treat
tpcktrypsin
sigmaaldrich
effici
ha
cleavag
trypsin
inactiv
trypsin
inhibitor
glycin
max
sigmaaldrich
prior
infect
mdck
cell
treat
indic
concentr
inhibitor
h
infect
mdck
cell
plate
vlp
ad
cell
presenc
compound
incub
h
cell
harvest
trypsin
incub
florigen
substrat
thermofish
scientif
cell
analyz
facsvers
system
bd
dead
cell
exclud
livedead
stain
livedead
fixabl
nearir
dead
cell
stain
kit
thermofish
scientif
week
old
mice
charl
river
franc
inject
ip
mgkg
paroxetin
dmso
pb
dmso
pb
solvent
h
prior
infect
mice
infect
ketamin
mgkg
xylazin
mgkg
anaesthesia
ip
pfu
kindli
provid
dr
f
krammer
icahn
school
medicin
mount
sinai
new
york
inocul
pb
via
intranas
rout
paroxetin
solvent
treatment
repeat
pi
first
group
mice
sacrif
pi
control
exposur
lung
snout
remov
asept
organ
homogen
ml
steril
pb
use
steril
steel
ceram
bead
ml
screw
cap
tube
use
beadblast
posit
homogen
benchmark
scientif
ms
two
time
break
ice
homogen
precipit
g
min
clear
supernat
analyz
infecti
viru
particl
use
standard
plaqu
assay
mdck
second
group
mice
monitor
daili
weight
loss
surviv
infect
mice
reach
human
endpoint
anim
procedur
accord
feder
regul
schweizer
bundesamt
bvet
control
institut
direct
de
l
animal
universit
de
genev
canton
author
commiss
cantonal
de
genev
pour
le
sur
le
animaux
approv
licens
